TRPM8 knockdown relieved inflammatory response and cell apoptosis in pneumonia model induced by Streptococcus...

Area of Science:

• Immunology
• Cell Biology
• Molecular Medicine

Background:

• Streptococcus pneumoniae causes significant pneumonia-related deaths globally.
• Transient Receptor Potential Melastatin 8 (TRPM8) is implicated in lung disease pathogenesis.
• Understanding TRPM8's role in pneumococcal pneumonia is crucial for developing new treatments.

Purpose of the Study:

• To investigate the role of TRPM8 in pneumococcal pneumonia.
• To elucidate the underlying molecular mechanisms of TRPM8's effects.
• To evaluate TRPM8 inhibition as a potential therapeutic strategy.

Main Methods:

• TRPM8 expression and inflammatory cytokine levels were measured in patient samples and A549 cells.
• siRNA-mediated TRPM8 knockdown was performed in A549 cells followed by S. pneumoniae infection.
• Cell viability, apoptosis, and inflammatory responses were assessed.
• The involvement of NF-κB/MAPK signaling pathways was investigated using Western blotting and pathway activators.

Main Results:

• TRPM8 was highly expressed in patients and cell models with pneumococcal pneumonia.
• Infection with S. pneumoniae upregulated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and activated NF-κB/MAPK signaling.
• TRPM8 knockdown attenuated S. pneumoniae-induced cell viability reduction, apoptosis, and inflammation.
• Inhibition of TRPM8 reduced the activation of NF-κB p-p65 and p-p38 MAPK.
• MAPK pathway activation reversed the protective effects of TRPM8 knockdown.

Conclusions:

• TRPM8 is upregulated during pneumococcal pneumonia and contributes to inflammation and apoptosis.
• TRPM8 knockdown alleviates pneumococcal pneumonia by inhibiting the NF-κB/MAPK signaling pathway.
• Targeting TRPM8 presents a promising therapeutic avenue for treating pneumococcal pneumonia.